Evidence map›Paper›PMID 42269714›Full record

ReviewACS nano2026

The Use of Deep Learning in RNA Therapeutic Development.

Deepak A Subramanian, Sophia L Yao, Alvin Chan, Jacob Witten, Daniel Reker, Daniel G Anderson, Robert Langer, Giovanni Traverso

Abstract readReview
In one paragraph

Review in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Deepak A SubramanianDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.ORCID 0000-0001-6224-7533
Sophia L YaoDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
Alvin ChanCollege of Computing and Data Science, Nanyang Technological University, Singapore 639798, Singapore.
Jacob WittenDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
Daniel RekerDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708, United States.ORCID 0000-0003-4789-7380
Daniel G AndersonDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.ORCID 0000-0003-0151-4903
Robert LangerDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.ORCID 0000-0003-4255-0492
Giovanni TraversoDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.ORCID 0000-0001-7851-4077

Funding

Nonviral delivery techniques for in vivo prime editingR01HL162564 · NHLBI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI DANIEL G ANDERSON · 2022 to 2026
$1.9M
NHLBI NIH HHS R01 HL162564
6 · The paper itself

Abstract

Ribonucleic acid (RNA)-based therapeutics have emerged as promising methods of disease treatment due to their ability to target the human genome and influence protein production, their versatility, and their relative lack of toxicity compared to other gene therapies. However, the RNA therapeutic design space is extremely large, encompassing multiple variables, including codon identities, secondary structure, and design of specific regions. RNA therapeutic optimization is difficult due to the impracticality of exploring such a vast design space experimentally. To address this limitation, deep learning methods have been employed to optimize RNA therapeutic development. In this review, we examine the application of deep learning models across three key aspects of RNA therapeutic development (RNA structure prediction, CRISPR activity, and RNA delivery), highlighting major contributions in these fields and analyzing how deep learning model architectures could affect model performance. We then discuss challenges associated with using deep learning for RNA therapeutics, such as computational and data limitations. Finally, we offer perspectives on areas for future exploration, such as emerging model architectures and methods of integration with more advanced high-throughput screening techniques. Ultimately, this review provides an overview of how deep learning is used in RNA therapeutic development and how it can evolve in the future.

Indexed as

Deep LearningGenetic TherapyRNAHumansNucleic Acid ConformationRNAcomputational modelingdeep learningdeliverygene editinghigh-throughput screeningneural networkRNAstructurevocabulary

Identifiers

PMID42269714
PMCPMC13557507

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.